The agreement extends Cepheid's reach beyond the hospital lab environment into the moderately complex lab space.
The test is the first of several planned CLIA-waived assays from Cepheid, and the first point-of-care test on the market to differentiate flu from RSV.
The partners are broadening their collaboration to bring point-of-care TB diagnostics to all levels of the health system in low- and middle-income countries.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
At the AMP meeting this week, JHU's Sara Sukumar discussed efforts to adapt a cell-free methylated DNA assay for breast cancer to a Cepheid Xpert cartridge.
The GenomeWeb Index was up around 2 percent, but its performance was well behind the broader stock market.
The firm claimed delays in a planned sales force expansion were partly to blame for lower-than-expected revenues; it also announced the FDA clearance of an assay for Trichomonas vaginalis.
The investment bank issued its downgrade citing concerns about changes to Cepheid's sales force and a flattening of its MRSA assay sales.
The firm reported results today in line with preliminary results reported last week, and affirmed its updated full-year guidance.
With recent and impending launches of POC MDx platforms, some industry observers believe the technology could replace some POC immunoassays in a few years.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.